At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 706 enrolled
Drug / intervention
CTP-543 matching placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
In Brief
A Phase 3 clinical trial evaluating CTP-543 matching placebo and CTP-543 for Alopecia Areata. Completed, enrolled 706 participants across 72 sites in 5 countries.
Detailed Summary
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesCanada, France, Poland, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartNov 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedAug 19, 2020
Enrollment StartNov 23, 2020
Primary CompletionApr 19, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.9 years ago
Interventions
CTP-543 matching placebodrug
Administered as tablets.
CTP-543drug
Administered as tablets.
CTP-543drug
Administered as tablets.